enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. FDA approves new COPD drug developed by firm in Raleigh ... - AOL

   www.aol.com/news/fda-approves-copd-drug...

   A new drug developed by a company with US headquarters in Raleigh, Ohtuvayre, was approved by the FDA Wednesday to help COPD patients manage symptoms.

3. US FDA approves Verona Pharma's inhaled COPD therapy - AOL

   www.aol.com/news/us-fda-approves-verona-pharmas...

   (Reuters) -The U.S. Food and Drug Administration has granted approval to a treatment from Verona Pharma for a chronic lung disease that commonly affects smokers, the U.K.-based company said on ...

4. The Most Exciting New Advances in Managing COPD - AOL

   www.aol.com/most-exciting-advances-managing-copd...

   For people with COPD—and their care providers—the future looks bright. ... Mail. 24/7 Help. For premium support please call: 800-290-4726 more ways to reach us. Mail. Sign in. Subscriptions ...

5. Doxofylline - Wikipedia

   en.wikipedia.org/wiki/Doxofylline

   Doxofylline (also known as doxophylline) is a phosphodiesterase inhibiting bronchodilator used in the treatment of chronic respiratory diseases such as asthma [1] and COPD. [2] Like theophylline, it is a xanthine derivative. [3] [4]

6. Bronchoscopic lung volume reduction - Wikipedia

   en.wikipedia.org/wiki/Bronchoscopic_lung_volume...

   BLVR was initially developed in the early 2000s [1] [2] as a minimally invasive treatment for severe COPD that is primarily caused by emphysema. BLVR evolved from earlier surgical approaches first developed in the 1950s [ 3 ] to reduce lung volume by removing damaged portions of the lungs via pneumonectomy or wedge resection .

7. Global Initiative for Chronic Obstructive Lung Disease

   en.wikipedia.org/wiki/Global_Initiative_for...

   [1] [2] They have organized the annual awareness day, World COPD Day, every November since 2002. [3] This organization issues recommendations for the treatment of chronic obstructive pulmonary disease and related medical conditions. GOLD issued its first formal recommendations in 2001. [2]